Science and technology company, Merck, has signed an agreement with HAPPYneuron, the Smart Health division of SBT Group and a pioneer of brain training industry, in which Merck will receive an exclusive license to the company’s cognitive remediation training programme for patients with multiple sclerosis (MS).
It’s estimated that approximately two million patients have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination.
HAPPYneuron’s suite of cognitive training games are designed to address the cognition challenges that people living with MS face, and the games automatically adjust skill to match the need of the individual – making the platform interesting for the patient and simple for healthcare professionals to use with their patients.
HAPPYneuron’s cognitive remediation programme will be available for inclusion in Merck’s MSdialog platform, when deemed beneficial for a patient by their healthcare provider. The in-licensing and integration of HAPPYneuron into Merck’s MSdialog platform will allow Merck to expand its first-of-its-kind eHealth solution for people living with MS.
MSdialog is a multi-tenant cloud-based software system for the management of MS that captures and presents patient outcome data to enable better decision-making by patients and providers. The software system provides patients with reminders to take their medication and monitors patient’s adherence information to their treatment and monitors clinical data.
MSdialog also allows MS patients to engage in the management of their disease by asking them to complete periodic health report questionnaires based on short forms of published instruments and standard scales, such as the Multiple Sclerosis Quality of Life Inventory (MSQLI) and the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaires.
“We have a long-standing commitment to delivering therapeutic and support solutions to people living with MS,” said Chief Marketing and Strategy Officer of Merck’s biopharma business, Rehan Verjee.
“The platform will enhance the attractiveness of MSdialog to patients and HCPs by seeking to address these cognitive deficit symptoms and further fostering the monitoring of the cognitive state of patients,” continued Verjee.
“We are very proud that Merck chose our programme,” said HAPPYneuron President, Franck Tarpin-Bernard.
“This agreement is a strong acknowledgement of the hard work we have achieved these past years to build training programmes adapted to the uniqueness of each medical condition. It reinforces our willingness to become a world leader of digital cognitive remediation,” continued Tarpin-Bernard.
MSdialog is currently available in 24 countries. MSdialog with HAPPYneuron will be made available to MS patients initially in a phased roll out beginning in Brazil, Argentina, Israel, Italy, France and the Netherlands.